Insider Selling: Cryolife Inc (CRY) CEO Sells 103,072 Shares of Stock
Cryolife Inc (NYSE:CRY) CEO James P. Mackin sold 103,072 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $32.17, for a total transaction of $3,315,826.24. Following the sale, the chief executive officer now owns 380,970 shares of the company’s stock, valued at approximately $12,255,804.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of NYSE:CRY opened at $32.25 on Friday. The company has a market cap of $1.21 billion, a PE ratio of 80.63 and a beta of 0.73. The company has a quick ratio of 3.63, a current ratio of 4.97 and a debt-to-equity ratio of 0.80. Cryolife Inc has a twelve month low of $16.80 and a twelve month high of $34.15.
Cryolife (NYSE:CRY) last released its quarterly earnings results on Monday, August 6th. The medical equipment provider reported $0.10 EPS for the quarter, beating the consensus estimate of $0.07 by $0.03. Cryolife had a negative net margin of 2.34% and a positive return on equity of 4.28%. The firm had revenue of $68.50 million during the quarter, compared to the consensus estimate of $64.08 million. During the same quarter in the prior year, the firm earned $0.12 EPS. Cryolife’s revenue for the quarter was up 43.2% on a year-over-year basis. equities research analysts forecast that Cryolife Inc will post 0.31 EPS for the current year.
Several analysts have recently weighed in on CRY shares. Zacks Investment Research upgraded shares of Cryolife from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Friday, May 11th. Northland Securities restated a “buy” rating and set a $32.00 price objective on shares of Cryolife in a research report on Tuesday, August 7th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 23rd. Finally, Canaccord Genuity boosted their price objective on shares of Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Cryolife currently has an average rating of “Buy” and a consensus price target of $32.75.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
See Also: What does EPS mean?
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.